Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Rev Med Virol. 2022 May;32(3):e2309. doi: 10.1002/rmv.2309. Epub 2021 Oct 22.
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.
接种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗是结束当前全球大流行的关键步骤。然而，在 2019 冠状病毒病（Covid-19）疫苗试验中，有几个特别脆弱的人群没有被足够数量地纳入。因此，随着科学的进步，为这些特殊人群接种 Covid-19 疫苗的建议将继续发展。本重点综述提供了针对这些特殊人群（即患有风湿和自身免疫性疾病、癌症、接受移植者、慢性肝病、终末期肾病、神经系统疾病、精神疾病、糖尿病、肥胖、心血管疾病、慢性阻塞性肺疾病、人类免疫缺陷病毒、当前吸烟者、孕妇和哺乳期妇女、老年人、儿童和有过敏反应的患者）的最新建议和考虑因素，使用的是当前可用的研究证据。
